Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tub... by Chiara Farroni, Anna Maria Gerarda Altera, Andrea Salmi, Valentina Vanini, Valentina Vanini, Gilda Cuzzi, Cecilia S. Lindestam Arlehamn, Alessandro Sette, Giovanni Delogu, Giovanni Delogu, Ivana Palucci, Settimia Sbarra, Alessandra Aiello, Andrea Picchianti-Diamanti, Gina Gualano, Fabrizio Palmieri, Delia Goletti, Elisa Petruccioli

“…A long-term stimulation assay was used to detect a memory response.ResultsThe IMID status and therapy did not affect the magnitude of response to Mtb-antigen stimulation and the number of responders. …”
Get full text

Against Futility Judgments for Patients with Prolonged Disorders of Consciousness by William Choi

“…“Mortality Associated with Withdrawal of Life-Sustaining Therapy for Patients with Severe Traumatic Brain Injury: A Canadian Multicentre Cohort Study.” …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active. Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA). …”
Get full text

Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Gua... by Jun Yu, Hao Liang, Fengxiang Qin, Junjun Jiang, Chunwei Qin, Yunxuan Huang, Bingyu Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, Chuanyi Ning, Yanyan Liao, Ning Zang, Jingzhen Lai, Wudi Wei, Li Ye, Xionglin Qin

“…ART could tend to be long-term, however, monitoring and management of liver damage among patients on ART are also important in clinical therapy.…”
Get full text

Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and prog... by Michaela Prchal-Murphy, Julia Zehenter, Marlene Fischer, Anita Pirabe, Madeleine Themanns, Behnaz Afrashteh, Eva Maria Putz, Karoline Kollmann, José Basílio, José Basílio, Manuel Salzmann, Wolfgang Strohmaier, Günther Krumpl, Alex Farr, Veronika Sexl, Michael Freissmuth, Eva Zebedin-Brandl

“…ObjectiveThe expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the toxicity associated with cell collection methods. …”
Get full text

Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model by Daisuke Kitano, Suguru Migita, Yuxin Li, Yutaka Koyama, Katsunori Fukumoto, Sayaka Shimodai-Yamada, Akira Onishi, Daiichiro Fuchimoto, Shunichi Suzuki, Yoshiyuki Nakamura, Atsushi Hirayama, Hiroyuki Hao, Yasuo Okumura

“…The objective of this study was to evaluate the safety and efficacy of DOAC monotherapy, specifically using factor Xa inhibitors such as edoxaban, in a low-density lipoprotein receptor knockout (LDL-R−/−) miniature pig model of human-like unstable coronary plaques compared to conventional dual-antiplatelet therapy (DAPT). Methods: We evaluated the safety and efficacy of edoxaban monotherapy in the LDL-R−/− pig model with human-like unstable coronary plaques induced by a high-cholesterol, high-fat diet. …”
Get full text

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma by Tianqi Luo, Zhijin Fan, Anyu Zeng, Anqi Wang, Yuanwei Pan, Yanyang Xu, Hongmin Chen, Weiqing Chen, Dingmeng Nie, Jiaming Lin, Anfei Huang, Ming Gong, Yufeng Huang, Yun Ding, Xiaojun Zhu, Lang Rao, Jin Wang

“…This targeted biomimetic co‐delivery system possesses several key features: 1) it can precisely target osteosarcoma with high B7H3 expression; 2) the combination of CDK4/6 inhibitors and PARP inhibitors exhibits synergistic effects, significantly impairing tumor's DNA repair capacity; and 3) the system has the potential for combination with photodynamic therapy, amplifying DNA repair defects to maximize tumor cell eradication. …”
Get full text

Intratumoural CD8+ CXCR5+ follicular cytotoxic T cells have prognostic value and are associated with CD19+ CD38+ B cells and tertiary lymphoid structures in colorectal cancer by Fangze Wei, Xiaotian Xu, Jing Wang, Shi Wen Mei, Fu Qiang Zhao, Fei Huang, Ti Xian Xiao, Guo Jing Wang, Baojun Wei, Shengkai Huang, Wei Cui

“…In MSS CRC, TFC cells function mostly in T cell activation and the cell cycle and have low expression of immune checkpoint molecules, which may influence the effectiveness of ICB therapy. TFC cells may regulate antitumor function by regulating CD19+ CD38+ B cells and TLSs.…”
Get full text

Quality of care delivery in patients with acute heart failure: insights from the international REPORT-HF registryResearch in context by Wan Ting Tay, Tiew-Hwa Katherine Teng, Wouter Ouwerkerk, Christiane E. Angermann, Kenneth Dickstein, John G.F. Cleland, Ulf Dahlstrom, Georg Ertl, Mahmoud Hassanein, Sergio V. Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Sean P. Collins, Gerasimos Filippatos, Carolyn S.P. Lam, Jasper Tromp

“…QIs that were least often achieved included measurement of natriuretic peptides, performance of echocardiography, treatment with guideline medical therapy, and a scheduled follow-up consultation after discharge. …”
Get full text

Chemo-proteomics reveals dihydrocaffeic acid exhibits anti-inflammation effects via Transaldolase 1 mediated PERK-NF-κB pathway by Guanjun Li, Huiying Li, Peili Wang, Xinzhou Zhang, Wenhua Kuang, Ling Huang, Ying Zhang, Wei Xiao, Qingfeng Du, Huan Tang, Jigang Wang

“…Dihydrocaffeic acid (DA), metabolite of chlorogenic acid, possesses potent pharmacologic activity for the therapy of a wide range of disorders and various biological properties, such as anti-inflammation. …”
Get full text

FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder by Li Ling, Wei Wei, Li Lin, Li Ke, Ye Chen, Li Ning, Wang Yu, Zhang Xin, Yang Rong, Zhang Xueying, Cui Jiaqu, Chen Qiyi, Qin Huanlong, Du Yasong, Zhao Xiaoxin, Lu Jubao, Lv Xiaoqiong, Ma Chunlian, Chen Shidong, Kuang Guifang, Zhao Dongmei, Fang Shuanfeng, Zhang Xujing, Yang Binrang, Wang Yanxia, Yuan Song, Zhou Xiang, Zhang Beihua, Jiang Lin, Ji Hong, Yan Yinmei, Yan Peihua, Huang Linsheng, Zhang Shaoyi, Ma Chenhuan, Miao Yun, Ling Wenqi, Geng Bojing, Feng Xueying, Li Huilin, Liu Liyan, Wu Weijia, Li Dexin, Jiang Qianru

“…The results of this trial will provide high-quality evidence to inform the future clinical application of this new therapy.Trial registration number ChiCTR2100043906; Pre-results.…”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…Subgroup analysis revealed that CP provided superior OS compared with P in patients with PD-L1 expression < 1%.ConclusionCP was a feasible and safe first-line therapy for patients with advanced NSCLC. Specifically, CP may function as a therapeutic alternative for individuals with low or negative PD-L1 expression, resulting in enhanced long-term outcomes compared to chemotherapy or P. …”
Get full text

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer by Sung Uk Bae, Hye Won Lee, Jee Young Park, Incheol Seo, Jae-Min Cho, Jin Young Kim, Ju Yup Lee, Yoo Jin Lee, Seong Kyu Baek, Nam Kyu Kim, Sang Jun Byun, Shin Kim

“…Methods: Tissue specimens from preoperative biopsy via sigmoidoscopy and surgical resection were obtained from 24 patients with locally advanced rectal cancer (LARC) who underwent neoadjuvant chemoradiation therapy (CRT) between August 2016 and December 2017. …”
Get full text

Single-cell atlas reveals multi-faced responses of losartan on tubular mitochondria in diabetic kidney disease by Zhen Zhu, Guangxin Luan, Song Wu, Yiyi Song, Shuang Shen, Kaiyue Wu, Shengnan Qian, Weiping Jia, Jun Yin, Tao Ren, Jianping Ye, Li Wei

“…Conclusions Our research suggests that scRNA-seq can reflect the multifaceted mitochondrial landscape of DKD renal tubular cells after drug treatment, and these findings may provide new targets for DKD therapy at the organelle level.…”
Get full text

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort by J. Ricardo McFaline-Figueroa, Lu Sun, Gilbert C. Youssef, Raymond Huang, Gang Li, Jiyoon Kim, Eudocia Q. Lee, Lakshmi Nayak, Ugonma Chukwueke, Rameen Beroukhim, Tracy T. Batchelor, E. Antonio Chiocca, Richard G. Everson, Lisa Doherty, Jennifer Stefanik, Kathryn Partridge, Amanda Spearman, Alexa Myers, Catharina Westergaard, Alyssa Russ, Maria Lavallee, Anna Smokovich, Corey LaForest-Roys, Rachel Garcia Fox, Christine McCluskey, Wenya Linda Bi, Omar Arnaout, PierPaolo Peruzzi, G. Rees Cosgrove, Keith L. Ligon, Isabel Arrillaga-Romany, Jennifer L. Clarke, David A. Reardon, Timothy F. Cloughesy, Robert M. Prins, Patrick Y. Wen

“…Our results demonstrate a clear pharmacodynamic effect of anti-PD1 therapy in glioblastoma and identify pathways that may mediate resistance. …”
Get full text

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk by Robert J.H. Miller, Majid Nabipoor, Erik Youngson, Gynter Kotrri, Nowell M. Fine, Jonathan G. Howlett, Ian D. Paterson, Justin Ezekowitz, Finlay A. McAlister

“…Conclusions Amongst patients with HFmrEF, those exhibiting positive LVEF trajectory were less likely to experience adverse outcomes after correcting for important confounders including medical therapy. Categorizing HFmrEF patients based on LVEF trajectory provides meaningful clinical information and may assist clinicians with management decisions.…”
Get full text

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms by Shivan Sivakumar, Ashwin Jainarayanan, Edward Arbe-Barnes, Piyush Kumar Sharma, Maire Ni Leathlobhair, Sakina Amin, David J. Reiss, Lara Heij, Samarth Hegde, Assaf Magen, Felicia Tucci, Bo Sun, Shihong Wu, Nithishwer Mouroug Anand, Hubert Slawinski, Santiago Revale, Isar Nassiri, Jonathon Webber, Gerard D. Hoeltzel, Adam E. Frampton, Georg Wiltberger, Ulf Neumann, Philip Charlton, Laura Spiers, Tim Elliott, Maria Wang, Suzana Couto, Thomas Lila, Pallavur V. Sivakumar, Alexander V. Ratushny, Mark R. Middleton, Dimitra Peppa, Benjamin Fairfax, Miriam Merad, Michael L. Dustin, Enas Abu-Shah, Rachael Bashford-Rogers

Get full text

The effectiveness of convalescent plasma administered on the first day of admission for COVID-19 patients: an open-label randomized controlled trial by Saeed Mohammadi, Mandana Pouladzadeh, Hamidreza Kouhpayeh, Shamsi Okati, Mehdi Safdarian, Peyman Eshghi, Parastoo Moradi Choghakabodi, Shahabeddin Mashaei, Sharareh Sanei Sistani, Yalda Khani, Soheila Nasizadeh, Ahmad Reza Shamshiri, Amir Teimourpour, Haijuan Wang

“…No side effects related to CP therapy were observed during infusion or follow-up. …”
Get full text

Assessing intrinsic capacity for person‐centred HIV care: a cross‐sectional study in ageing populations in Malaysia and Hong Kong by Reena Rajasuriar, Syaza Hisham, John Son Lim, Jean Yi Cheong, Wen Ying Ho, Siew Hwei Yap, Nurul Syuhada Zulhaimi, Malinee Neelamegam, Catherine Cheung, Vivian Wong, Ruhana Che Yusof, Kejal Hasmukharay, Shahrul Bahyah Kamaruzzaman, Sharifah Faridah Syed Omar, Meng Li Chong, Pui Li Wong, Grace Chung‐Yan Lui

“…All PWH received antiretroviral therapy (ART) for a median duration of 11 (8−14) years. …”
Get full text

Serological Profile of Anti-<i>Toxoplasma gondii</i> Antibodies in Liver Transplant Recipients by Gabriella Beltrame Pintos, Francielly Camilla Bazílio Laurindo Pires, Nathália Zini, Rita Cássia Martins Alves da Silva, Francisco Inaldo Mendes Silva Junior, Renato Ferreira da Silva, Tainara Souza Pinho, Luiz Carlos de Mattos, Cinara Cássia Brandão

“…Allied with immunosuppressive therapy, the presence of latent infection in recipients elevates the risk of severe toxoplasmosis. …”
Get full text